Please login to the form below

Not currently logged in
Email:
Password:

The Editors blog

An inside look at what’s happening within the pharma industry and across the PMGroup from the PMLiVE editorial team

Jeux sans frontières

From regulations to customs, 2018 has some big questions to answer

Pharma and Brexit

Here at PMLiVE we began this year anticipating a year of change for pharma and, sure enough, we end the year knowing where the EMA is headed.

But, despite its impending Amsterdam move, 2017 has provided pharma with more questions than answers when it come to Brexit.

That’s particularly true if we try to guess the future shape of UK-EU pharma regulatory relations and the MHRA’s post-Brexit role.

The MHRA could only tell me it is working closely with the government. “We are clear, as is the government, on our desire to retain a close working partnership in respect of medicines regulation after the UK leaves the EU,” a spokesperson said.

“As part of the exit negotiations the UK will discuss with the EU and Member States how best to continue cooperation in the field of medicines regulation in the best interests of business, citizens and patients in both the UK and the EU.”

So, that’s clear then... perhaps.

At least the first phase of the negotiations will no longer hold up the vital next stage of the process.

But even when phase two kicks off in the new year, there are major questions to be faced about customs arrangements and trade deals, in addition to medicines regulations.

For now all that we can hope for is that these games with our frontiers will be played properly in 2018.

Article by
Dominic Tyer

Director of Editorial, PMGroup

22nd December 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
foxandcat.online

some pressure is helpful but too much of the wrong sort quickly takes its toll. we help creatove agenices manage...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...